AFREEN QURAISHI: Open Payments
NPI 1366957466 · PRINCETON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,627 in 85 payments from 16 companies in 2025. Trend: 2023 $87 · 2024 $515 · 2025 $1,627
Food & beverage: $1,627
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $311 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $226 |
| UCB, Inc. | 12 | $187 |
| Incyte Corporation | 9 | $142 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $133 |
| GENZYME CORPORATION | 5 | $93 |
| Regeneron Healthcare Solutions, Inc. | 5 | $86 |
| Galderma Laboratories, L.P. | 5 | $86 |
| ABBVIE INC. | 5 | $77 |
| Lilly USA, LLC | 3 | $58 |
Products named: TREMFYA, NEFFY, Bimzelx, DUPIXENT, OPZELURA, RINVOQ, ILUMYA, NEMLUVIO.
Industry payments across NJ — which companies pay providers there.
